Coherus BioSciences Shares Fall Following Q2 Sales Guidance

Coherus BioSciences CHRS announced that UDENYCA preliminary unaudited net sales for the second quarter expected in the range of $79 million-$84 million.

Coherus BioSciences shares were trading lower by 13% at $19.77 on Monday morning. The stock has a 52-week high of $23.43 and a 52-week low of $8.32.

Related Links:

Fast Track Designation By FDA Granted For Prevail's Parkinson's Treatment

Sol-Gel Technologies Shares Positive Results For Skin Breakout Cream